{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T20:04:15Z","timestamp":1760645055189,"version":"build-2065373602"},"reference-count":16,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2005,6,14]],"date-time":"2005-06-14T00:00:00Z","timestamp":1118707200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomedical Chromatography"],"published-print":{"date-parts":[[2006,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Atazanavir is the most recently introduced protease inhibitor for the suppression of the anti\u2010human immunodefficiency virus. A sensitive and selective reversed\u2010phase liquid chromatographic assay for this drug in human plasma has been developed and validated. Atazanavir was isolated from a 500 \u00b5L plasma sample using liquid\u2013liquid extraction with dichloromethane. After evaporation and reconstitution of the extract the sample was analysed using liquid chromatography and ultraviolet detection at 280 nm. In the evaluated concentration range (44\u20134395 ng[sol ]mL atazanavir), intra\u2010day precisions were \u22647% and inter\u2010day precisions were \u226414%. Accuracies between 96 and 106% were found. The lower limit of quantification was 44 ng[sol ]mL with an intra\u2010day precision of 7%, an inter\u2010day precision of 14% and an accuracy of 87%. There was no interference from 32 tested potentially co\u2010administrated drugs and metabolites. The usefulness of the assay was demonstrated for samples obtained from an HIV\u2010infected patient treated with atazanavir. Copyright \u00a9 2005 John Wiley &amp; Sons, Ltd.<\/jats:p>","DOI":"10.1002\/bmc.530","type":"journal-article","created":{"date-parts":[[2005,6,14]],"date-time":"2005-06-14T06:46:46Z","timestamp":1118731606000},"page":"72-76","source":"Crossref","is-referenced-by-count":15,"title":["Liquid chromatographic assay for the protease inhibitor atazanavir in plasma"],"prefix":"10.1002","volume":"20","author":[{"given":"Rolf W.","family":"Sparidans","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frits","family":"Dost","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristel M. L.","family":"Crommentuyn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alwin D. R.","family":"Huitema","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan H. M.","family":"Schellens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos H.","family":"Beijnen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2005,6,14]]},"reference":[{"key":"e_1_2_1_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0378-4347(01)00344-9"},{"key":"e_1_2_1_3_1","unstructured":"Center for Drug Evaluation and Research of the US Department of Health and Human Services Food and Drug Administration.Guidance for industry\u2014bioanalytical method validation 2001;http:\/\/www.fda.gov\/cder\/guidance\/4252fnl.htm(access date 30 November 2004)."},{"key":"e_1_2_1_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchromb.2004.07.008"},{"key":"e_1_2_1_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchromb.2004.01.041"},{"key":"e_1_2_1_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchromb.2004.10.005"},{"key":"e_1_2_1_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0925-4439(02)00089-3"},{"key":"e_1_2_1_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1570-0232(02)01002-4"},{"key":"e_1_2_1_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1570-0232(03)00589-0"},{"key":"e_1_2_1_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1570-0232(02)00728-6"},{"key":"e_1_2_1_11_1","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1093\/ajhp\/61.13.1365","article-title":"Atazanavir: A new protease inhibitor to treat HIV infection","volume":"61","author":"Musial BL","year":"2004","journal-title":"American Journal of Health\u2010Systems and Pharmaceutics"},{"key":"e_1_2_1_12_1","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1D394"},{"key":"e_1_2_1_13_1","doi-asserted-by":"publisher","DOI":"10.1081\/JLC-100101455"},{"key":"e_1_2_1_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1570-0232(03)00063-1"},{"key":"e_1_2_1_15_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1007669411738"},{"key":"e_1_2_1_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0378-4347(00)00163-8"},{"key":"e_1_2_1_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1570-0232(02)00822-X"}],"container-title":["Biomedical Chromatography"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fbmc.530","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/analyticalsciencejournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/bmc.530","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T19:39:51Z","timestamp":1760038791000},"score":1,"resource":{"primary":{"URL":"https:\/\/analyticalsciencejournals.onlinelibrary.wiley.com\/doi\/10.1002\/bmc.530"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,6,14]]},"references-count":16,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2006,1]]}},"alternative-id":["10.1002\/bmc.530"],"URL":"https:\/\/doi.org\/10.1002\/bmc.530","archive":["Portico"],"relation":{},"ISSN":["0269-3879","1099-0801"],"issn-type":[{"type":"print","value":"0269-3879"},{"type":"electronic","value":"1099-0801"}],"subject":[],"published":{"date-parts":[[2005,6,14]]}}}